论文部分内容阅读
采用免疫组织化学SP法检测Ki67在20例卵巢良性肿瘤、10例交界性肿瘤、42例卵巢癌中的表达,并分析它们与卵巢临床病理指标的关系。结果:卵巢良性肿瘤KI指数为2.00±1.22,交界肿瘤为10.20±5.03,卵巢癌为35.20±15.20,三组比较,差异显著(P<0.01);Ⅲ~Ⅳ期卵巢癌KI指数为35.75±12.30,显著高于Ⅰ~Ⅱ期卵巢癌的22.00±11.20(P<0.01);中低分化癌KI指数为34.17±9.08,显著高于高分化癌的22.88±10.02(P<0.01);卵巢癌Ki指数与组织类型、淋巴转移无关(P>0.05)。结果表明,卵巢癌中Ki67表达显著高于卵巢良性交界肿瘤,可作为鉴别良恶性肿瘤的指标;其表达与卵巢癌的临床分期、病理分级有关。
Immunohistochemical SP method was used to detect the expression of Ki67 in 20 cases of benign ovarian tumors, 10 cases of borderline tumors and 42 cases of ovarian cancer. The relationship between Ki67 and clinicopathological parameters was analyzed. Results: The KI index of benign ovarian tumor was 2.00 ± 1.22, the borderline tumor was 10.20 ± 5.03, the ovarian cancer was 35.20 ± 15.20, the difference between the three groups was significant (P <0.01); The KI index of Ⅲ ~ Ⅳ ovarian cancer was 35.75 ± 12.30 , Significantly higher than that of stage Ⅰ-Ⅱ ovarian cancer (22.00 ± 11.20, P <0.01). The KI of poorly differentiated carcinoma was 34.17 ± 9.08, significantly higher than that of well-differentiated carcinoma (22.88 ± 10.02, P <0.01) Index and tissue type, lymph node metastasis (P> 0.05). The results showed that Ki67 expression in ovarian cancer was significantly higher than benign border ovarian tumors, which can be used as an index to identify benign and malignant tumors; its expression is related to the clinical stage and pathological grade of ovarian cancer.